Cancer-Related Mutations in the Sam Domains of EphA2 Receptor and Ship2 Lipid Phosphatase: A Computational Study

被引:2
|
作者
Vincenzi, Marian [1 ]
Mercurio, Flavia Anna [1 ]
Autiero, Ida [1 ]
Leone, Marilisa [1 ]
机构
[1] Inst Biostruct & Bioimaging, Via Pietro Castellino 111, I-80131 Naples, Italy
来源
MOLECULES | 2024年 / 29卷 / 05期
关键词
Sam domain; EphA2; Ship2; Mid Loop (ML); End Helix (EH); AlphaFold2; molecular dynamics; cancer; WEB SERVER; EVOLUTIONARY CONSERVATION; BINDING-AFFINITY; NMR STRUCTURE; PROTEIN; STABILITY; SEQUENCE; DYNAMICS; DIAGRAMS; PROGRAM;
D O I
10.3390/molecules29051024
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The lipid phosphatase Ship2 interacts with the EphA2 receptor by forming a heterotypic Sam (sterile alpha motif)-Sam complex. Ship2 works as a negative regulator of receptor endocytosis and consequent degradation, and anti-oncogenic effects in cancer cells should be induced by hindering its association with EphA2. Herein, a computational approach is presented to investigate the relationship between Ship2-Sam/EphA2-Sam interaction and cancer onset and further progression. A search was first conducted through the COSMIC (Catalogue of Somatic Mutations in Cancer) database to identify cancer-related missense mutations positioned inside or close to the EphA2-Sam and Ship2-Sam reciprocal binding interfaces. Next, potential differences in the chemical-physical properties of mutant and wild-type Sam domains were evaluated by bioinformatics tools based on analyses of primary sequences. Three-dimensional (3D) structural models of mutated EphA2-Sam and Ship2-Sam domains were built as well and deeply analysed with diverse computational instruments, including molecular dynamics, to classify potentially stabilizing and destabilizing mutations. In the end, the influence of mutations on the EphA2-Sam/Ship2-Sam interaction was studied through docking techniques. This in silico approach contributes to understanding, at the molecular level, the mutation/cancer relationship by predicting if amino acid substitutions could modulate EphA2 receptor endocytosis.
引用
收藏
页数:26
相关论文
共 27 条
  • [21] A Novel Oncogenic Role of Inositol Phosphatase SHIP2 in ER-Negative Breast Cancer Stem Cells: Involvement of JNK/Vimentin Activation
    Fu, Chiung-Hui
    Lin, Ruey-Jen
    Yu, John
    Chang, Wen-Wei
    Liao, Guo-Shiou
    Chang, Wen-Ying
    Tseng, Ling-Ming
    Tsai, Yi-Fang
    Yu, Jyh-Cherng
    Yu, Alice L.
    STEM CELLS, 2014, 32 (08) : 2048 - 2060
  • [22] The PI3K effector Arap3 interacts with the PI(3,4,5)P3 phosphatase SHIP2 in a SAM domain-dependent manner
    Raaijmakers, Judith H.
    Deneubourg, Laurence
    Rehmann, Holger
    de Koning, John
    Zhang, Zhongchun
    Krugmann, Sonja
    Erneux, Christophe
    Bos, Johannes L.
    CELLULAR SIGNALLING, 2007, 19 (06) : 1249 - 1257
  • [23] Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients - A retrospective cohort study
    Monami, M.
    Lamanna, C.
    Pala, L.
    Bardini, G.
    Cresci, B.
    Francesconi, P.
    Balzi, D.
    Marchionni, N.
    Rotella, C. M.
    Mannucci, E.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (03) : 184 - 189
  • [24] A comprehensive computational study on pathogenic mis-sense mutations spanning the RING2 and REP domains of Parkin protein
    Biswas, Ria
    Bagchi, Angshuman
    GENE, 2017, 610 : 49 - 58
  • [25] Somatic Mutations and Intratumoral Heterogeneity of Cancer-Related Genes NLK, YY1 and PA2G4 in Gastric and Colorectal Cancers
    Son, Hyun Ji
    Choi, Eun Ji
    Yoo, Nam Jin
    Lee, Sug Hyung
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2813 - 2815
  • [26] Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
    Slatkin, Neal
    Zaki, Naim
    Wang, Steven
    Louie, John
    Sanga, Panna
    Kelly, Kathleen M.
    Thipphawong, John
    JOURNAL OF PAIN, 2019, 20 (04) : 440 - 452
  • [27] Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection-A Double Blind, Multi-Center, Randomized Phase IV Study
    Wang, Cheng-Hsu
    Lin, Cheng-Yao
    Chen, Jen-Shi
    Ho, Ching-Liang
    Rau, Kun-Ming
    Tsai, Jo-Ting
    Chang, Cheng-Shyong
    Yeh, Su-Peng
    Cheng, Chieh-Fang
    Lai, Yuen-Liang
    CANCERS, 2019, 11 (02):